Moderna and Merck announced a breakthrough on August 24, 2026, with their personalised mRNA-based cancer vaccine reducing melanoma recurrence in a large-scale clinical study. This marks the first successful mRNA cancer vaccine in a major trial.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
It is the first time that an mRNA-based cancer vaccine has succeeded in a large-scale study.
www.straitstimes.com/world/united... Moderna and Merck's personalised mRNA cancer vaccine lowers melanoma recurrence, marking a breakthrough in targeted cancer treatment research. Read more at straitstimes.com. Read more at straitstimes....